12.05

8.27% 0.815

Arrowhead Pharmaceuticals Inc (ARWR)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché ARWR Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$11.24

Aprire:

$11.04

Volume 24 ore:

1.92M

Relative Volume:

1.01

Capitalizzazione di mercato:

$1.40B

Reddito:

$181.74M

Utile/perdita netta:

$-599.49M

Rapporto P/E:

-2.4062

EPS:

-5.01

Flusso di cassa netto:

$-604.32M

1 W Prestazione:

-1.38%

1M Prestazione:

-17.77%

6M Prestazione:

-40.61%

1 anno Prestazione:

-45.50%

Intervallo 1D:

$10.95

$12.50

Intervallo di 1 settimana:

$10.92

$12.93

Portata 52W:

$9.57

$30.41

Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile

Nome

Arrowhead Pharmaceuticals Inc

Settore

Healthcare (1152)

Industria

Biotechnology (660)

Telefono

626-696-4702

Indirizzo

177 E COLORADO BLVD, PASADENA, CA

Dipendente

525

Cinguettio

@ArrowheadPharma

Prossima data di guadagno

2025-02-10

Ultimi documenti SEC

ARWR's Discussions on Twitter

Confronta ARWR con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ARWR Arrowhead Pharmaceuticals Inc	12.05	1.40B	181.74M	-599.49M	-604.32M	-5.01
VRTX Vertex Pharmaceuticals Inc	476.92	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	560.59	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	597.70	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	231.91	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	229.69	26.16B	3.81B	-644.79M	-669.77M	-6.24

Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-06-05	Iniziato	Goldman	Neutral
2023-12-04	Iniziato	BofA Securities	Buy
2023-09-19	Iniziato	Citigroup	Neutral
2023-07-21	Iniziato	TD Cowen	Outperform
2023-05-12	Downgrade	SVB Securities	Outperform → Market Perform
2023-04-26	Iniziato	SMBC Nikko	Outperform
2023-04-12	Aggiornamento	SVB Securities	Market Perform → Outperform
2023-03-21	Iniziato	Bernstein	Mkt Perform
2022-09-09	Iniziato	Morgan Stanley	Equal-Weight
2022-05-11	Aggiornamento	Robert W. Baird	Neutral → Outperform
2022-01-19	Ripresa	Goldman	Buy
2021-08-06	Reiterato	Chardan Capital Markets	Buy
2021-06-04	Ripresa	Robert W. Baird	Neutral
2021-02-05	Reiterato	H.C. Wainwright	Buy
2020-12-21	Downgrade	Robert W. Baird	Outperform → Neutral
2020-12-16	Iniziato	UBS	Buy
2020-11-19	Iniziato	Citigroup	Buy
2020-05-13	Iniziato	RBC Capital Mkts	Outperform
2020-05-08	Aggiornamento	Oppenheimer	Perform → Outperform
2020-04-15	Aggiornamento	Cantor Fitzgerald	Neutral → Overweight
2020-03-24	Aggiornamento	SVB Leerink	Underperform → Mkt Perform
2020-03-17	Iniziato	Goldman	Neutral
2020-01-21	Iniziato	SVB Leerink	Underperform
2019-12-13	Iniziato	Oppenheimer	Perform
2019-11-29	Reiterato	Chardan Capital Markets	Buy
2019-11-27	Reiterato	B. Riley FBR	Buy
2019-11-25	Aggiornamento	Robert W. Baird	Neutral → Outperform
2019-10-24	Downgrade	Robert W. Baird	Outperform → Neutral
2019-10-22	Reiterato	Chardan Capital Markets	Buy
2019-10-03	Iniziato	Robert W. Baird	Outperform
2018-09-07	Aggiornamento	B. Riley FBR	Neutral → Buy
2018-09-06	Reiterato	Chardan Capital Markets	Buy
2018-08-08	Reiterato	Cantor Fitzgerald	Overweight
2018-07-02	Reiterato	Chardan Capital Markets	Buy

Mostra tutto

Arrowhead Pharmaceuticals Inc Borsa (ARWR) Ultime notizie

Apr 15, 2025

Arrowhead CFO Ken Myszkowski to retire, Daniel Apel to succeed - MSN

Apr 15, 2025

Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer - BioSpace

Apr 15, 2025

Arrowhead (ARWR) Announces CFO Transition as Ken Myszkowski Reti - GuruFocus

Apr 15, 2025

Arrowhead appoints new CFO as Myszkowski retires By Investing.com - Investing.com UK

Apr 15, 2025

Apr 14, 2025

Long Term Trading Analysis for (ARWR) - news.stocktradersdaily.com

Apr 14, 2025

Arrowhead Pharmaceuticals Insider Sold Shares Worth $1,533,337, According to a Recent SEC Filing - marketscreener.com

Apr 14, 2025

Apr 12, 2025

Arrowhead Pharmaceuticals CEO sells $1.53 million in stock By Investing.com - Investing.com Canada

Apr 12, 2025

Arrowhead Pharmaceuticals CEO sells $1.53 million in stock - Investing.com Australia

Apr 12, 2025

Apr 11, 2025

Arrowhead Pharmaceuticals CEO Sells Over $1.5 Million in Company Stock - TradingView

Apr 11, 2025

Apr 09, 2025

ARROWHEAD RESEARCH : Increases Ownership in Ablaris to 64% - MarketScreener

Apr 09, 2025

Apr 06, 2025

Insiders Could Have Profited By Holding onto Arrowhead Pharmaceuticals Shares Despite 23% Drop - simplywall.st

Apr 06, 2025

Apr 04, 2025

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Business Wire

Apr 04, 2025

Arrowhead Pharmaceuticals Expands Team with 34,190 RSU Grants to New Hires - Stock Titan

Apr 04, 2025

Apr 03, 2025

Arrowhead stock hits 52-week low at $11.92 amid market challenges - Investing.com Canada

Apr 03, 2025

Apr 01, 2025

Rnai Technology Market Generated Opportunities, Future Scope - openPR.com

Apr 01, 2025

Mar 27, 2025

Rnai Technology Market Set to Witness Significant Growth - openPR

Mar 27, 2025

Mar 26, 2025

Arrowhead stock hits 52-week low at $14.21 amid market challenges - Investing.com Canada

Mar 26, 2025

Mar 25, 2025

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is favoured by institutional owners who hold 70% of the company - Yahoo Finance

Mar 25, 2025

Mar 21, 2025

RNA Therapies Clinical Trials and Pipeline 2025: EMA, PDMA, FDA Approvals, Medication, IND, NDA Approval, Therapies, Mechanism of Action, Route of Administration and Companies by DelveInsight - The Globe and Mail

Mar 17, 2025

First Capital REIT Announces March 2025 Distribution - The Globe and Mail

Mar 17, 2025

Mar 12, 2025

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by US Bancorp DE - Defense World

Mar 12, 2025

Bank of New York Mellon Corp Sells 36,341 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World

Mar 12, 2025

Mar 11, 2025

Arrowhead stock holds Buy rating, $80 target from H.C. Wainwright By Investing.com - Investing.com UK

Mar 11, 2025

Mar 10, 2025

Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases - AOL.com

Mar 10, 2025

Institutional investors may adopt severe steps after Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) latest 4.2% drop adds to a year losses - Simply Wall St

Mar 10, 2025

Buy Rating for Arrowhead Pharmaceuticals Driven by Promising ARO-C3 Trial Results and Strategic Pipeline Advancements - TipRanks

Mar 10, 2025

Arrowhead Pharmaceuticals Stock Dips Despite Promising Study - TipRanks

Mar 10, 2025

Mutual of America Capital Management LLC Sells 1,519 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World

Mar 10, 2025

Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy - BioSpace

Mar 10, 2025

Arrowhead Pharmaceuticals Says Study for Complement-Mediated Disease Therapy Shows C3 Reduction in Patients - Marketscreener.com

Mar 10, 2025

Arrowhead Pharma Reports Positive Topline Data From Phase 1/2 Study Of ARO-C3 - Nasdaq

Mar 10, 2025

Arrowhead Pharmaceuticals Announces Topline Results From Part 2 Of Phase 1/2 Study Of Aro-C3 In Patients With IgA Nephropathy - Marketscreener.com

Mar 10, 2025

Arrowhead Clinical Trial: 87% C3 Reduction in IgA Nephropathy Patients - StockTitan

Mar 10, 2025

Mar 07, 2025

Arrowhead Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025

Pharma Pulse 3/7/25: Overcoming Health Data Blockages in Polypharmacy, How Insurers Responded to Disasters & more - Pharmaceutical Executive

Mar 07, 2025

Mar 06, 2025

Arrowhead Pharmaceuticals CEO sells $5.27 million in stock By Investing.com - Investing.com South Africa

Mar 06, 2025

Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases - Lelezard

Mar 06, 2025

Arrowhead Pharmaceuticals Presents Data on Two Clinical-Stage Candidates for Obesity Treatment - Marketscreener.com

Mar 06, 2025

Arrowhead advances RNAi obesity treatments in clinical trials - Investing.com

Mar 06, 2025

Arrowhead advances RNAi obesity treatments in clinical trials By Investing.com - Investing.com UK

Mar 06, 2025

Mar 05, 2025

Arrowhead Pharmaceuticals CEO sells $5.27 million in stock - Investing.com

Mar 05, 2025